AstraZeneca and Forest Laboratories to initiate phase III clinical trials for ceftazidime/avibactam to treat serious Gram-negative bacterial infections

Tuesday, 18 October 2011

AstraZeneca and Forest Laboratories, Inc. announced today that ceftazidime/avibactam (CAZ-AVI) will enter phase III trials to investigate efficacy in treating hospitalised patients with serious Gram-negative bacterial infections including Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI). CAZ-AVI combines a broad-spectrum cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam, formerly NXL104) to overcome antibiotic-resistance and treat the increasing number of infections resistant to existing therapies.

View full press release

Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar